Skip to main content

Table 5 Risk of SPC by first and second cancer site among female patients, France 1989–2004 (N = 129,160)

From: The effect of patient characteristics on second primary cancer risk in France

First cancer site Second cancer site O E PYR SIRa EARa,b (95% CI)
Head and neck Head and neckc 57 0.61 7,781 93.83 72.5 (54.7-94.1)
  Lung, bronchus and trachea 51 2.71   18.81 62.1 (45.3-82.7)
  Oesophagus 20 0.41   49.33 25.2 (15.2-39.2)
  Liver, primary 5 0.69   7.25 5.5 (1.2-14.1)
Oesophagus Head and neck 10 0.14 1,244 71.04 79.3 (37.4-146.7)
Colorectum Breast 297 246.36 87,123 1.21 5.8 (2.0-9.9)
  Colorectumc 98 67.48   1.45 3.5 (1.4-6.0)
  Corpus uteri 66 41.93   1.57 2.8 (1.0-4.8)
Liver, primary Lung, bronchus and trachea 5 0.61 1,709 8.13 25.7 (5.8-64.7)
  Non-Hodgkin’s lymphoma 3 0.53   5.62 14.4 (0.4-48.2)
  Soft tissue 2 0.06   32.96 11.3 (1.0-41.9)
Larynx Lung, bronchus and trachea 19 0.74 1,995 25.76 91.5 (53.6-145.0)
  Head and neck 10 0.22   45.47 49.0 (22.9-91.1)
  Oesophagus 3 0.11   26.70 14.5 (2.5-43.4)
  Bladder 3 0.28   10.73 13.6 (1.6-42.5)
Lung, bronchus and trachea Head and neck 10 0.99 9,446 10.09 9.5 (4.0-18.4)
  Bladder 6 1.18   5.11 5.1 (1.1-12.6)
  Oesophagus 3 0.47   6.41 2.7 (0.1-8.8)
Soft tissue Ovary and uterine adnexa 4 0.86 3,951 4.68 8.0 (0.6-23.8)
Melanoma of skin Breast 98 75.05 32,127 1.31 7.1 (1.4-13.8)
  Kidney 15 5.32   2.82 3.0 (1.0-6.0)
Breast Corpus uteri 358 147.83 351,434 2.42 6.0 (5.0-7.1)
Cervix uteri Lung, bronchus and trachea 34 7.66 28,122 4.44 9.4 (5.6-14.2)
  Colorectum 40 22.60   1.77 6.2 (2.1-11.3)
  Vagina and vulva 10 1.28   7.82 3.1 (1.2-6.1)
  Leukaemia 12 4.17   2.88 2.8 (0.7-6.0)
  Bladder 10 2.45   4.08 2.7 (0.8-5.7)
Corpus uteri Breast 174 120.03 41,147 1.45 13.1 (7.1-19.9)
  Colorectum 106 60.33   1.76 11.1 (6.4-16.5)
  Lung, bronchus and trachea 34 17.06   1.99 4.1 (1.6-7.4)
Vagina and vulva Cervix uteri 6 0.68 4,219 8.87 12.6 (3.6-29.4)
  Bladder 4 0.88   4.53 7.4 (0.5-22.2)
  Head and neck 3 0.47   6.37 6.0 (0.3-19.7)
Kidney Breast 62 46.58 17,327 1.33 8.9 (0.6-19.0)
  Lung, bronchus and trachea 16 6.61   2.42 5.4 (1.5-11.2)
  Leukaemia 11 4.07   2.70 4.0 (0.8-9.0)
  Thyroid gland 8 2.70   2.96 3.1 (0.4-7.5)
Thyroid gland Leukaemia 13 3.95 31,397 3.29 2.9 (0.9-5.8)
Hodgkin’s disease Leukaemia 5 0.50 6,930 10.05 6.5 (1.6-16.1)
  Non-Hodgkin’s lymphoma 5 0.73   6.89 6.2 (1.3-15.8)
  Lung, bronchus and trachea 4 0.97   4.14 4.4 (0.2-13.4)
Non-Hodgkin’s lymphoma Stomach 12 5.02 22,997 2.39 3.0 (0.5-6.9)
  Kidney 12 4.99   2.41 3.0 (0.5-6.9)
Chronic lymphatic leukaemia Breast 41 26.30 9,091 1.56 16.2 (3.4-32.3)
Acute myeloid leukaemia Ovary and uterine adnexa 3 0.48 2,491 6.26 10.1 (0.5-33.3)
  1. SPC, second primary cancer; O, Observed; E, Expected; PYR, person-years at risk; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval.
  2. aAll P < .05.
  3. bNumber of excess cancers per 10,000 person-years at risk.
  4. cSPC occurring in a different subsite as the first primary cancer.